EUVIMEDEUVIMED entdecken
Open Access

Risk of Incident Melanoma Among Individuals With Low-Count Monoclonal B-Cell Lymphocytosis

Bryan A Vallejo iD, Ahmed Ansari iD, Sameer A Parikh, Sara J Achenbach, Kari G Rabe iD, Aaron D Norman iD, Janet E Olson iD, Neil E Kay iD, Esteban Braggio iD, Curtis A Hanson, Celine M Vachon iD, James R Cerhan iD und 3 weitere

Journal of Clinical Oncology · 10.12.2024 · 42 (35) · 4153-4162

DOI: 10.1200/jco.24.00332 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Oncology, erschienen am 10.12.2024. Verfasst von Bryan A Vallejo und 14 weiteren Autor:innen. Beteiligte Einrichtung: Division of Computational Biology, Mayo Clinic, Rochester, MN. Hauptthemen laut MEDLINE: Melanoma, Lymphocytosis, B-Lymphocytes. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIA NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Chronic lymphocytic leukemia (CLL)–phenotype monoclonal B-cell lymphocytosis (MBL) is a premalignant condition that is roughly 500-fold more common than CLL. It is unknown whether the two-fold increased risk of developing melanoma associated with CLL extends to individuals with MBL. METHODS Using the Mayo Clinic Biobank, we identified participants who were 40 years or older with no previous hematological malignancies, who resided in the 27 counties around Mayo Clinic, and who had available biospecimens for screening. Eight-color flow cytometry was used to screen for MBL. Individuals with MBL were classified as low-count MBL (LC-MBL) or high-count MBL on the basis of clonal B-cell percent. Incident melanomas were identified using International Classification of Diseases codes and confirmed via medical records review. Cox regression models were used to estimate hazard ratios (HRs) and 95% CI. RESULTS Of the 7,334 participants screened, 1,151 were identified with a CD5-positive MBL, of whom 1,098 had LC-MBL. After a median follow-up of 3.2 years (range, 0-13.5), 131 participants developed melanoma, of whom 36 individuals were positive for MBL. The estimated 5-year cumulative incidence of melanoma was 3.4% and 2.0% among those with and without MBL, respectively. After adjusting for age, sex, and history of previous melanoma, individuals with MBL exhibited a 1.86-fold (95% CI, 1.25 to 2.78) risk of melanoma. This elevated risk persisted when analysis was restricted to those without a history of melanoma (HR, 2.05 [95% CI, 1.30 to 3.23]). Individuals with LC-MBL had a 1.92-fold (95% CI, 1.29 to 2.87) increased risk of developing melanoma overall and a 2.74-fold increased risk (95% CI, 1.50 to 5.03) of melanoma in situ compared with those without MBL. CONCLUSION LC-MBL is associated with an approximately two-fold increased risk of melanoma overall and a 2.74-fold increased risk of melanoma in situ.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaLymphocytosisB-LymphocytesHumansMaleFemaleMiddle AgedAgedIncidenceAdultRisk FactorsSkin NeoplasmsLeukemia, Lymphocytic, Chronic, B-CellAged, 80 and over

Autor:innen und Institutionen

  • Division of Computational Biology, Mayo Clinic, Rochester, MN.
  • Department of Dermatology, Mayo Clinic, Rochester, MN.
  • Division of Hematology, Mayo Clinic, Rochester, MN.
  • Division of Clinical Trials and Biostatistics, Mayo Clinic, Rochester, MN.
  • Division of Epidemiology, Mayo Clinic, Rochester, MN.
  • Department of Immunology, Mayo Clinic, Rochester, MN.

ORCID-Profile: Bryan A Vallejo, Ahmed Ansari, Kari G Rabe, Aaron D Norman, Janet E Olson, Neil E Kay, Esteban Braggio, Celine M Vachon, James R Cerhan, Tait D Shanafelt, Susan L Slager

Förderung

  • NCI NIH HHS
  • NIA NIH HHS

Zitieren

APA

Vallejo, B. A., Ansari, A., Parikh, S. A., Achenbach, S. J., Rabe, K. G., Norman, A. D., Olson, J. E., Kay, N. E., Braggio, E., Hanson, C. A., Vachon, C. M., Cerhan, J. R., Baum, C. L., Shanafelt, T. D., & Slager, S. L. (2024). Risk of Incident Melanoma Among Individuals With Low-Count Monoclonal B-Cell Lymphocytosis. Journal of Clinical Oncology, 42(35), 4153-4162. https://doi.org/10.1200/jco.24.00332

Vancouver

Vallejo BA, Ansari A, Parikh SA, Achenbach SJ, Rabe KG, Norman AD, et al. Risk of Incident Melanoma Among Individuals With Low-Count Monoclonal B-Cell Lymphocytosis. Journal of Clinical Oncology. 2024;42(35):4153-4162. doi:10.1200/jco.24.00332

BibTeX
@article{Vallejo2024,
  author = {Vallejo, Bryan A and Ansari, Ahmed and Parikh, Sameer A and Achenbach, Sara J and Rabe, Kari G and Norman, Aaron D and Olson, Janet E and Kay, Neil E and Braggio, Esteban and Hanson, Curtis A and Vachon, Celine M and Cerhan, James R and Baum, Cristian L and Shanafelt, Tait D and Slager, Susan L},
  title = {Risk of Incident Melanoma Among Individuals With Low-Count Monoclonal B-Cell Lymphocytosis},
  journal = {Journal of Clinical Oncology},
  year = {2024},
  volume = {42},
  number = {35},
  pages = {4153--4162},
  doi = {10.1200/jco.24.00332}
}
Kostenlos starten →